Label: LEUKOTRAP WB SYSTEM kit

  • NDC Code(s): 53157-262-01
  • Packager: Haemonetics Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated January 26, 2022

If you are a consumer or patient please visit this version.

  • DOSAGE & ADMINISTRATION

    CP2D Anticoagulant Solution and AS-3 Solution may be used with Haemonetics

    apheresis devices. See the Haemonetics Operation Manual for full operating

    instructions.

    Prior to use of the solutions, check the solutions for leaks by squeezing each of the

    bags firmly. If leaks are found, discard the solution.

  • PRINCIPAL DISPLAY PANEL

    Envelope Label

  • INGREDIENTS AND APPEARANCE
    LEUKOTRAP WB SYSTEM 
    leukotrap wb system kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:53157-262
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:53157-262-011 in 1 KIT; Type 1: Convenience Kit of Co-Package
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 10 BAG 1 mL  in 63 
    Part 20 BAG 1 mL  in 100 
    Part 1 of 2
    ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE 
    anticoagulant citrate phosphate double dextrose injection, solution
    Product Information
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE (UNII: IY9XDZ35W2) (DEXTROSE - UNII:IY9XDZ35W2) DEXTROSE3.21 g  in 63 mL
    Inactive Ingredients
    Ingredient NameStrength
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 0.206 g  in 63 mL
    SODIUM CITRATE (UNII: 1Q73Q2JULR) 1.66 g  in 63 mL
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) 0.14 g  in 63 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    163 mL in 1 BAG; Type 1: Convenience Kit of Co-Package
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDABN820915
    Part 2 of 2
    ADDITIVE SOLUTION - 3 
    additive solution - 3 injection, solution
    Product Information
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ADENINE (UNII: JAC85A2161) (ADENINE - UNII:JAC85A2161) ADENINE0.03 g  in 100 mL
    DEXTROSE (UNII: IY9XDZ35W2) (DEXTROSE, UNSPECIFIED FORM - UNII:IY9XDZ35W2) DEXTROSE1.1 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) 0.276 g  in 100 mL
    SODIUM CITRATE (UNII: 1Q73Q2JULR) 0.588 g  in 100 mL
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 0.41 g  in 100 mL
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 0.042 g  in 100 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1100 mL in 1 BAG; Type 1: Convenience Kit of Co-Package
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDABN82091509/23/1983
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDABN82091509/22/1983
    Labeler - Haemonetics Corporation (057827420)
    Establishment
    NameAddressID/FEIBusiness Operations
    Haemonetics Manufacturing Inc078598396manufacture(53157-262)